WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010023854) CANCER RELATED GENE, LGN/GPSM2
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/023854    International Application No.:    PCT/JP2009/004017
Publication Date: 04.03.2010 International Filing Date: 21.08.2009
IPC:
C12N 15/09 (2006.01), A61K 31/7088 (2006.01), A61P 35/00 (2006.01), C12Q 1/68 (2006.01)
Applicants: ONCOTHERAPY SCIENCE, INC. [JP/JP]; 2-1, Sakado 3-chome, Takatsu-ku, Kawasaki-shi, Kanagawa 2130012 (JP) (For All Designated States Except US).
NAKAMURA, Yusuke [JP/JP]; (JP) (For US Only).
KATAGIRI, Toyomasa [JP/JP]; (JP) (For US Only).
FUKUKAWA, Chikako [JP/JP]; (JP) (For US Only)
Inventors: NAKAMURA, Yusuke; (JP).
KATAGIRI, Toyomasa; (JP).
FUKUKAWA, Chikako; (JP)
Agent: SHIMIZU, Hatsushi; (JP)
Priority Data:
61/190,395 27.08.2008 US
Title (EN) CANCER RELATED GENE, LGN/GPSM2
(FR) GÈNE LGN/GPSM2 ASSOCIÉ AU CANCER
Abstract: front page image
(EN)The present invention provides methods for detecting and diagnosing cancer, which method involves the determination of the expression level of the LGN/GPSM2 gene. Furthermore, the present invention provides methods of screening for therapeutic agents useful in the treatment or prevention of cancer and methods for treating breast cancer. Moreover, the present invention provides siRNAs targeting the LGN/GPSM2 gene, which are useful in the treatment or prevention of cancer.
(FR)Cette invention concerne des méthodes de détection et de diagnostic du cancer, lesdites méthodes impliquant la détermination du taux d’expression du gène LGN/GPSM2. L’invention concerne par ailleurs des méthodes de criblage d’agents thérapeutiques servant à traiter ou à prévenir le cancer et des méthodes de traitement du cancer du sein. L’invention concerne aussi des ARNsi ciblant le gène LGN/GPSM2, qui sont utilisés dans le traitement ou la prévention du cancer.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)